We examined the association between arterial stiffness using non-invasive pulse wave velocity (PWV) and cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers. We conducted a cross-sectional multivariate logistic regression analysis using established cut-off values for PWV and CSF biomarkers. Of the 739 participants, 69% were female, 84% were White, 12% were Black, and the mean age was 62. After adjustment for potential confounders, participants with high PWV had 94% (OR = 1.94, 95% CI 1.20–3.20) greater odds of AD biomarker positivity for tTau/Aβ42 and 108% (OR = 2.08, 95% Cl, 1.27–3.46) for pTau181/Aβ42. Our results suggest that higher arterial stiffness is associated with AD CSF biomarker positivity.
MatthewsKAXuWGagliotiAH, et al.Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged ≥65 years. Alzheimers Dement2019; 15: 17–24.
2.
Budd HaeberleinSAisenPSBarkhofF, et al.Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis2022; 9: 197–210.
3.
DyckCvSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
4.
ShiMChuFZhuF, et al.Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: a focus on aducanumab and lecanemab. Front Aging Neurosci2022; 14: 870517.
5.
BatemanRJXiongCBenzingerTLS, et al.Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med2012; 367: 795–804.
6.
GeorgakasJEHoweMDThompsonLI, et al.Biomarkers of Alzheimer’s disease: past, present and future clinical use. Biomark Neuropsychiatry2023; 8: 100063.
7.
HampelHBlennowKShawLM, et al.Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol2010; 45: 30–40.
8.
SunderlandTLinkerGMirzaN, et al.Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA2003; 289: 2094–2103.
9.
HanssonOSeibylJStomrudE, et al.CSF Biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement2018; 14: 1470–1481.
10.
OrtnerMLanzKGoldhardtO, et al.Elecsys cerebrospinal fluid immunoassays accurately detect Alzheimer’s disease regardless of concomitant small vessel disease. J Alzheimers Dis2023; 93: 1537–1549.
11.
HanssonORutzSCorradiniV, et al.Establishment of updated biomarker cut-off values for the second-generation Elecsys β-amyloid(1–42), pTau and tTau CSF immunoassays. Alzheimers Dement2021; 17: e053883.
12.
Iturria-MedinaYSoteroRCToussaintPJ, et al.Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun2016; 7: 11934.
13.
SalviP. Pulse waves: How vascular hemodynamics affects blood pressure. Cham: Springer International Publishing, 2017.
14.
LaurentSBoutouyriePAsmarR, et al.Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 19792001; 37: 1236–1241.
15.
Alvarez-BuenoCCunhaPGMartinez-VizcainoV, et al.Arterial stiffness and cognition among adults: a systematic review and meta-analysis of observational and longitudinal studies. J Am Heart Assoc2020; 9: e014621.
16.
CooperLLO'DonnellABeiserAS, et al.Association of aortic stiffness and pressure pulsatility With global amyloid-β and regional tau burden among Framingham Heart Study participants without dementia. JAMA2022; 79: 710–719.
17.
Sáiz-VazquezOPuente-MartínezAPacheco-BonrostroJ, et al.Blood pressure and Alzheimer’s disease: a review of meta-analysis. Front Neurol2023; 13: 1065335.
18.
HajjarIGoldsteinFCMartinGS, et al.Roles of arterial stiffness and blood pressure in hypertension-associated cognitive decline in healthy adults. Hypertension2016; 67: 171–175.
19.
GoetzMEHanfeltJJJohnSE, et al. Rationale and design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology2019; 53: 187–200.
20.
GoetzMEHanfeltJJJohnSE, et al.Rationale and design of the emory healthy aging and emory healthy brain studies. Neuroepidemiology2019; 53: 187–200.
21.
Roche. FDA grants Breakthrough Device Designation for Roche’s Elecsys Cerebrospinal Fluid (CSF) Assays to Support the Improved Diagnosis of Alzheimer’s disease, https://www.roche.com/media/releases/med-cor-2018-07-20 (2018).
22.
BittnerTZetterbergHTeunissenCE, et al.Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid. Alzheimers Dement2016; 12: 517–526.
23.
Van BortelLMLaurentSBoutouyrieP, et al.Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens2012; 30: 445–448.
24.
BrunoRMBianchiniEFaitaF, et al.Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovasc Ultrasound2014; 12: 34.
25.
van HoutMJDekkersIALinL, et al.Estimated pulse wave velocity (ePWV) as a potential gatekeeper for MRI-assessed PWV: a linear and deep neural network based approach in 2254 participants of the Netherlands Epidemiology of Obesity study. Int J Cardiovasc Imaging2022; 38: 183–193.
26.
BaldoMPCunhaRSRibeiroALP, et al.Racial differences in arterial stiffness are mainly determined by blood pressure levels: results from the ELSA-brasil study. J Am Heart Assoc2017; 6: e005477.
27.
CameloLVMachadoAVChorD, et al.Racial discrimination is associated with greater arterial stiffness and carotid intima-media thickness: the ELSA-brasil study. Ann Epidemiol2022; 72: 40–47.
28.
BlennowKStomrudEZetterbergH, et al.Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease. Clin Chem Lab Med2023; 61: 234–244.
29.
BlennowKShawLMStomrudE, et al.Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays. Sci Rep2019; 9: 19024.
30.
MoonSWByunMSYiD, et al.The ankle–brachial index is associated with cerebral β-amyloid deposition in cognitively normal older adults. J Gerontol Ser A2019; 74: 1141–1148.
31.
SnyderHMCorriveauRACraftS, et al.Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimers Dement2015; 11: 710–717.
32.
RouchLCestacPSallerinB, et al.Pulse wave velocity is associated with greater risk of dementia in mild cognitive impairment patients. Hypertension2018; 72: 1109–1116.
33.
GoldMERogersSCKulshreshthaA, et al.Contribution of peripheral microvascular dysfunction to mild cognitive impairment. Am J Cardiol2024; 218: 4–6.
34.
HughesTMWagenknechtLECraftS, et al.Arterial stiffness and dementia pathology. Neurology2018; 90: e1248–e1256.
35.
BoylePAYuLLeurgansSE, et al.Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Ann Neurol2019; 85: 114–124.
36.
BurkeGLHughesTM. Arterial changes connecting hypertension to Alzheimer’s disease and related dementias. JACC Cardiovasc Imaging2021; 14: 186–188.
37.
EliasMFRobbinsMABudgeMM, et al.Arterial pulse wave velocity and cognition with advancing age. Hypertension2009; 53: 668–673.
38.
WaldsteinSRRiceSCThayerJF, et al.Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension2008; 51: 99–104.
RitchieCSmailagicaNNoel-StorrAH, et al.CSF Tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev2017; 3: CD010803.
41.
Oijen M van, HofmanASoaresHD, et al.Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol2006; 5: 655–660.
42.
Pérez-GrijalbaVRomeroJPesiniP, et al.Plasma Aβ42/40 ratio detects early stages of Alzheimer’s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J Prev Alzheimers Dis2019; 6: 34–41.
43.
LuiJKLawsSMLiQ-X, et al.Plasma amyloid-β as a biomarker in Alzheimer’s disease: the AIBL study of aging. J Alzheimers Dis2010; 20: 1233–1242.
